News

Sharps Technology’s SC Asset Purchase and $200 Million Syringe Sales Agreement Paves the Way to Begin Producing Prefillable Specialty Copolymer Syringes in the U.S.

Sharps CEO issues letter to shareholders with details about the InjectEZ acquisition, establishing Sharps position in the prefillable syringe (PFS)…

2 years ago

Autonomix Medical, Inc. Reports Full Year 2024 Financial Results and Provides Corporate Update

Year marked by operational and clinical execution advancing the development of a potential breakthrough technology for the nervous system Continued…

2 years ago

Generation Lab Introduces First Platform that Measures Aging & Treatment Efficacy to Help Extend the Human Healthspan

Backed by decades of longevity science, platform measures “biological noise” to determine age and fitness of key body systems aimed…

2 years ago

Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus

Clinical testing of LP-310 expected to commence in mid-2024 Patient recruitment is underway for Phase 2a multicenter, dose-ranging study PITTSBURGH,…

2 years ago

Milestone® Pharmaceuticals to Participate in the Upcoming Jefferies Global Healthcare Conference

MONTREAL and CHARLOTTE, N.C., May 31, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST) today announced that members of its…

2 years ago

Novartis Scemblix® Phase III data first to show superior efficacy with a favorable safety and tolerability profile vs. standard-of-care TKIs in adults with newly diagnosed CML

Phase III ASC4FIRST trial met both primary endpoints with clinically meaningful and statistically significant results; Scemblix® (asciminib) demonstrated superior MMR…

2 years ago

SS Innovations Engages BDO as its new Auditor

SS Innovations believes that the selection of BDO will facilitate uplisting of its common stock to a National Securities Exchange…

2 years ago

Morphic to Participate in Jefferies Global Healthcare Conference

WALTHAM, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral…

2 years ago

Aptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

SAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX:…

2 years ago

Bionomics Limited Announces Private Placement of up to $70.0 Million

ADELAIDE, Australia and CAMBRIDGE, Mass., May 31, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”), a…

2 years ago